Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Antolin J, Amerigo MJ, Cantabrana A, Roces A, Jimenez P: Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune ... resulting in hypoalbuminaemia and associated clinical sequelae. Gastrointestinal Manifestations of Systemic Lupus Erythematosus ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

Discover Cabaletta Bio's promising CAR T-cell therapy for autoimmune diseases! Durable efficacy, FDA support, and clinical ...

Research findings increasingly indicate close associations between autoimmune thyroid disease and rheumatic disease.

Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...